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Introduction
Copper-64 is a radionuclide produced by a cyclotron with an 
intermediate half-life (T
1/2
 = 12.7 h) that decays by both β+ (655 
keV, 17.4%) and β- (573 keV, 39.0%) emission, making it suitable 
for labeling monoclonal antibodies (mAbs) for positron emission 
tomography (PET) imaging and radioimmunotherapy (RIT) of 
cancer. Previous experiments in xenograft-bearing rodent mod-
els have demonstrated tumor cytotoxicity of internalizing 64Cu 
radiopharmaceuticals superior to other nuclides, but at much 
lower tumor absorbed doses.
Two studies in particular offer tantalizing evidence of cyto-
toxicity in addition to traditional radiation damage mechanisms. 
Connett and others reported 82% complete tumor responses 
to the 64Cu-labeled mAb 1A3 in Golden Syrian hamsters bear-
ing GW39 xenografts, at a tumor absorbed dose of only 586 
rad (5.86 Gy).1 Lewis and others reported complete, but tem-
porary, tumor remissions using the somatostatin analogue 
Background: We previously described a two-antibody model of 64Cu radioimmunotherapy to evaluate low-dose, solid-
tumor response. This model was designed to test the hypothesis that cellular internalization is critical in causing tumor 
cell death by mechanisms in addition to radiation damage. The purpose of the present study was to estimate radiation 
dosimetry for both antibodies (mabs) using positron emission tomography (peT) imaging and evaluate the effect of 
internalization on tumor growth.
Results: Dosimetry was similar between therapy groups. Median time to tumor progression to 1 g ranged from 7–12 
days for control groups and was 32 days for both treatment groups (p < 0.0001). No statistically significant difference 
existed between any control group or between the treatment groups.
Material and Methods: In female nude mice bearing Ls174T colon carcinoma xenografts, tumor dosimetry was cal-
culated using serial peT images of three mice in each group of either internalizing 64Cu-labeled DOTa-cBR96 (DOTa = 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or non-internalizing 64Cu-labeled DOTa-cT84.66 from 3 to 48 h. 
For the therapy study, controls (n = 10) received saline, DOTa-cBR96 or DOTa-cT84.66. Treatment animals (n = 9) received 
0.890 mCi of 64Cu-labeled DOTa-cBR96 or 0.710 mCi of 64Cu-labeled DOTa-cT84.66. Tumors were measured daily.
Conclusions: peT imaging allows the use of 64Cu for pre-therapy calculation of tumor dosimetry. In spite of highly 
similar tumor dosimetry, an internalizing antibody di  not improve the outcome of 64Cu radioimmunotherapy. Radio-
resistance of this tumor cell line and copper efflux may have confounded the study. Further investigations of the thera-
peutic efficacy of 64Cu-labeled mabs will focus on interaction between 64Cu and tumor suppressor genes and copper 
chaperones.
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64Cu-TETA-Tyr3-octreotate in the highly aggressive CA20948 
rat pancreatic tumor model at a low tumor absorbed dose.2 
Evaluation of intracellular distribution of 64Cu offers some 
potential insight into additional cytotoxicity mechanisms. In 
vivo distribution studies in rats of 64Cu-TETA-octreotide demon-
strated transchelation of 64Cu to superoxide dismutase (SOD) in 
the liver.3 Other experiments identified 64Cu from 64Cu-TETA-
octreotide in the nucleus (19.5%) and mitochondria (21.1%) of 
AR42J rat pancreatic tumor cells in vitro over a 24 h period.4 As 
there was no evidence that the somatostatin analogue itself had 
accumulated in these locations, it is possible that 64Cu transche-
lates to copper cofactor enzymes, metalloproteins and copper-
handling chaperones following internalization.
We previously reported the development and characteriza-
tion of a two-antibody model for comparison of 64Cu RIT.5 We 
confirmed the internalization of the mAb cBR96 which recog-
nizes the Lewisy ceramide variant present in multiple human 
and veterinary carcinomas.6,7 We also confirmed that the mAb 
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tumor response to an internalizing versus a non- 
internalizing mAb at the calculated tumor absorbed 
dose of 10 Gy in a mouse xenograft model of cancer.
Results
PET/CT imaging. Representative PET/CT images 
for both 64Cu-labeled mAbs at time points from 
3–48 h are shown in Figure 1. Tumor uptake was 
heterogeneous in most studies at the 24 and 48 h time 
points (Fig. 2). Tumor uptake of 64Cu-DOTA-cBR96 
was 5.06% ID/organ at 3 h, 12.38% ID/organ at 
26 h and 16.12% ID/organ at 48 h. Tumor uptake 
for 64Cu-DOTA-cT84.66 was 7.25% ID/organ at 3 h, 
17.45% ID/organ at 25 h and 20.24% ID/organ at 
49 h. There were no statistically significant differences 
between conjugates at any time point, although the 
power of the test is limited due to the small numbers 
of mice that could be imaged daily. This pattern of 
uptake was different from that seen in the traditional 
biodistribution studies in which tumor accumulation 
of 64Cu-DOTA-cBR96 was significantly more rapid 
at 3 h than that of 64Cu-DOTA-cT84.66. Using a 
Monte Carlo N-particle Transport Code,12 the calcu-
lated absorbed dose to the tumors was 484 rad/mCi 
(131 mGy/MBq) for 64Cu-DOTA-cBR96 and 643 
rad/mCi (174 mGy/MBq) for 64Cu-DOTA-cT84.66.
Qualitative analysis of the PET images revealed 
few regions of radioactivity accumulation that were 
not predicted by the traditional biodistribution stud-
ies. What did appear unexpectedly in the 3 h images 
for 64Cu-DOTA-cBR96 was radioactivity associ-
ated with the vascular bed of the tail base. A lesser 
accumulation of radioactivity was visible in the tail 
of mice receiving 64Cu-DOTA-cT84.66, likely associ-
ated with small, perivascular leakage at the injection 
site. This radioactivity largely washed out in both 
cases over the subsequent 48 h period. Minor intesti-
nal uptake was visible in the 48 h scan of mice receiv-
ing 64Cu-DOTA-cBR96. As with the traditional 
biodistribution studies,5 the hepatic radioactivity of 
64Cu-DOTA-cT84.66 was clearly greater than that of 
64Cu-DOTA-cBR96. This was best illustrated by the 48 h images 
depicted in Figure 1C. Intestinal radioactivity was clearly visible 
in mice imaged with 64Cu-DOTA-cT84.66 at 48 h.
Therapy study. The growth curves of the tumors are presented 
in Figure 3. Aggressive, unrestricted tumor growth was evident 
for the three control groups. Both experimental groups displayed 
a tumor growth delay, followed by unrestricted tumor growth. 
Abrupt decline in tumor volume was recorded for 22 of the 48 
mice in the study. This decrease represented sudden ulceration 
and collapse of the tumor. The majority of these events occurred 
when tumor masses reached 1 g or larger. Mice were sacrificed 
when the tumor mass reached 3 g, the tumor developed severe 
ulceration or the tumor impaired the ability of the mouse to 
ambulate. Because of the tendency to ulcerate at a tumor burden 
cT84.66,8 which recognizes carcinoembryonic antigen (CEA) 
is non-internalizing.5 This antigen is also present on numerous 
human carcinomas8 and reported in veterinary hepatocellular 
carcinomas, rete testis mucinous adenocarcinomas and choroid 
plexus carcinomas.9-11 The biodistributions of these antibodies 
were characterized in an LS174T nude mouse model of colon 
cancer and tumor dosimetry was estimated.5
The purpose of these experiments was to test the hypothesis 
that internalization of 64Cu is the single necessary step in caus-
ing low-dose cytotoxicity with RIT of cancer. An imaging study 
was performed to test the hypothesis that the actual tumor dose 
received from the therapeutic administration would be equiva-
lent between the two 64Cu-labeled mAbs. A RIT experiment 
was performed to test our overarching hypothesis by comparing 
Figure 1.  Representative peT/CT fusion scans at time points of approximately 3, 
24 and 48 h. The 64Cu-DOTa-cBR96 mice are presented above, and the 64Cu-DOTa-
cT84.66 mice are presented below. Note the subtle, but important, differences in the 
patterns of distribution to the tumor and normal organs for each mouse imaged over 
a 2 day period. Much more activity is visible in the tail base region for all 64Cu-DOTa-
cBR96 conjugates. Increased liver and intestine activity from biliary excretion is 
visible with 64Cu-DOTa-T84.66, particularly in (C).
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stable ligand would have resulted in more favorable intracellular 
trafficking. Boswell and others have described a cross-bridged 
cyclam with greater stability than traditional chelators such as 
DOTA.15 Similarly, a bombesin peptide labeled with 64Cu using 
the chelator NOTA (NOTA = 1,4,7-triaazacyclononane-1,4,7-
triacetic acid) demonstrated greater in vivo stability than a simi-
lar peptide conjugated with DOTA.16 However, intranuclear 
accumulation has been reported to be inhibited by more stable 
chelation in at least one model.17
The large difference in mAb dose between the biodistribution 
and therapy studies prompted us to confirm the tumor dosime-
try by PET imaging studies. In the biodistribution experiments, 
different groups of mice were sacrificed at each time point. As 
such, mice exhibiting unusual clearance properties would be 
randomly distributed throughout the pool of animals, thwarting 
a systematic understanding of the pattern of microscopic anti-
body metabolism in the tumor. Furthermore, the injected dose 
of radiation and mAb in the biodistribution studies was nearly 
one log below the therapeutic dose, leaving open the possibility 
that a larger dose of antibody might be distributed differently. 
over 1 g, the most meaningful end point was the time to progres-
sion of tumor mass to 1 g. The Kaplan-Meier curve describing 
time to progression is presented in Figure 4. The median time 
to progression to 1 g ranged from 7–12 days for the three control 
populations. The median time to progression to 1 g was 32 days 
for both of the experimental groups. There was no statistically 
significant difference between the medians among the control 
groups of saline and unlabeled antibodies. The two experimental 
groups were also statistically indistinguishable; however, there 
was a statistically significant difference between the experimental 
and control groups (p = 0.0001). There was no evidence of toxic-
ity in any of the mice in the experimental groups or the control 
groups receiving unlabeled mAbs.
Discussion
This therapy study yielded mixed results, some expected and 
some surprising. As hypothesized it is clear from the similarity 
between the saline control and the unlabeled DOTA-cBR96 and 
DOTA-cT84.66 groups that the mAbs did not initiate antibody-
dependent cellular cytotoxicity (ADCC) in these animals. There 
was no significant difference between the times to progression to 
1 g tumor mass, and no growth delay was observed in the mice 
receiving unlabeled antibodies compared to the mice receiving 
saline. Although an in vitro study previously demonstrated evi-
dence for direct cytotoxicity as well as ADCC by unmodifi d 
BR96,7 to our knowledge there are no in vivo experiments that 
confirm this effect. The lack of direct cytotoxicity or ADCC in 
this study may be due to ambient concentrations below those 
which would be optimal for cell killing or potentially due to 
interference with this mechanism by DOTA conjugation. In 
either case antibody-induced immune response did not affect the 
outcome of this therapy study.
What was unexpected was the lack of support for the 
hypothesis that internalization is the single critical step in the 
unusual cytotoxicity previously demonstrated for internalizing 
64Cu-labeled radiopharmaceuticals. Our in vitro studies con-
firmed the internalizing property of 64Cu-DOTA-cBR96 and the 
non-internalizing properties of 64Cu-DOTA-cT84.66.5 However, 
the 64Cu efflux studies previously published offer the possibil-
ity that a lack of persistence of 64Cu within the cells to interact 
with copper chaperones after internalization may explain the lack 
of differential therapeutic efficacy between these two mAbs.5 
Cellular efflux has not been evaluated for 64Cu- and 131I-labeled 
1A3 in GW39 cells, used in the experiment in which 64Cu-BAT-
2IT-1A3 exhibited markedly superior tumor responses (Anderson 
CJ, personal communication). Rapid efflux of internalized 64Cu 
is a tempting explanation for the results of these experiments, but 
remains speculative as cellular efflux is difficult to quantify in 
vivo. What is likely, however, is that the trafficking of 64Cu into 
the nucleus and mitochondria previously described in reference 4, 
would cause accumulation, and thus residualization, of radioac-
tivity within the cells. Recently, trafficking of 64Cu to the nucleus 
has been associated with the expression of wild-type p53.13 The 
LS174T cell line expresses wild-type p53, but did not show evi-
dence of residualization.14 It is possible that chelation with a more 
Figure 2. Representative two-dimensional slices through the tumor 
region for one mouse each from the 64Cu-DOTa-cBR96 (left) and 64Cu-
DOTa-cT84.66 (right) treatment groups at 24 h. The plane depicted in 
the peT/CT image denotes the origin of the two-dimensional transaxial 
slice. The ellipse depicted denotes the region of interest of the tumor, 
but is not equivalent to the very precise ROI drawn around the tumor 
regions for peT dosimetry calculation.
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as attenuation were likely to introduce negligible error into the 
calculations.
As previously discussed, the low abundance of β+ emission 
from 64Cu decay allows for efficient imaging of therapeutic 
doses of the radiolabeled mAbs. Thus, a full therapy dose, rather 
than a tracer dose, may be administered to observe biodistri-
bution under conditions of greater mAb concentration relative 
to antigen pool. Qualitative evaluation of the imaging studies 
detected little distribution to tissue that was not predicted by the 
results of the sacrificial studies. However, endothelial binding 
of 64Cu-DOTA-cBR96 in the tail vasculature was unexpected. 
In retrospect, this uptake may have been masked in the tradi-
tional biodistribution data because the tail was counted with the 
caudal half of the carcass. As with the circulating CEA pool 
A more ideal dosimetry study would follow the distribution of 
the 64Cu-labeled mAbs in the same group of living mice over 
a 48 h period. This experiment would allow a more complete 
understanding of the progression of distribution of the mAbs 
and 64Cu within the animals. An animal that cleared antibody or 
radioactivity rapidly in the reticuloendothelial system would be 
identified and accounted for in the modeling of the subsequent 
therapy experiment. The ability to image the distribution of the 
64Cu-labeled mAbs with PET permits this quantification of bio-
distribution, including tumor targeting. Minor limitations exist 
in the ability to quantify the radioactivity within a region of 
the PET scan. However, because of the small size of the mouse, 
the energy of the annihilation photons detected (511 keV), as 
well as the subcutaneous location of the tumors, factors such 
Figure 3. (a–e) Tumor growth curves for each control and experimental group. Tumor volumes are expressed in mm3 and time is in days from treat-
ment, after 14 days of tumor growth. plot (a) represents the saline control mice. plot (B) represents the unlabeled DOTa-cBR96 control mice.  
plot (C) represents the unlabeled DOTa-cT84.66 control mice. plot (D) are the 64Cu-DOTa-cBR96 experimental mice. plot (e) are the 64Cu-DOTa-cT84.66 
experimental mice. Large decreases in tumor volume were due to ulceration and necrosis of those tumors.
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evaluation with repeated measures to give greater power to the 
analysis. When therapy studies are performed, individual mice 
could be screened with a tracer dose and therapeutic mass, in order 
to compare biodistributions, metabolism and tumor uptakes. 
From this test dose, the appropriate dose to deliver the desired 
tumor absorbed dose could be calculated, ensuring that all mice 
receive the intended dose. These mice could then be imaged again 
after the therapy dose to confirm expected distributions. Using this 
method, future therapy studies of 64Cu-labeled delivery platforms 
could be better controlled, yielding more meaningful results.
In the case of this therapy study, the results of the imaging 
analysis suggested that the mice did, indeed, receive equivalent 
tumor absorbed doses from 64Cu-labeled mAbs. This lends fur-
ther support to the veracity of the outcome, suggesting that the 
hypothesis tested cannot be supported by this two-antibody 
system and tumor model. Although internalization appeared 
in previous studies to be necessary for the enhanced cytotoxic-
ity of 64Cu-labeled radiopharmaceuticals, the new information 
reported here suggests that cellular characteristics of copper 
handling or activity of apoptotic pathways may also play a large 
role in the cytotoxic mechanism. In vitro, LS174T cells clearly 
expressed mechanisms by which 64Cu from both mAbs was 
removed from the cell into the extracellular matrix. This would 
be expected for a non-internalizing mAb like cT84.66, as CEA 
is shed continuously, but internalization of cBR96 should have 
resulted in residualization of radioactivity within the cell. Future 
evaluation of these agents must continue to focus on the fate of 
64Cu within the target cell.
Material and Methods
Cell line. The LS174T cell line was obtained from the American 
Type Culture Collection (Manassas, VA). Immediately prior 
for 64Cu-DOTA-cT84.66, the endothelial sink for deposition of 
radioactivity may account for the delayed tumor accumulation 
of 64Cu-DOTA-cBR96, as detected by PET imaging, relative to 
the traditional biodistribution analysis.5 Vascular endothelial 
binding did not appear to diminish total tumor uptake, and 
the tumor distribution remained similar between the two mAbs 
at 24 and 48 h post-injection. Minor intestinal activity was 
observed in mice treated with 64Cu-DOTA-cBR96. Intestinal 
cross-reactivity with cBR96 has not been previously reported in 
mice.7 It has, however, been identified in the large intestine of 
dogs.6 It is not surprising that some cross-reactivity with nor-
mal tissue would exist. Consistent with sacrificial biodistribu-
tion results, 64Cu-DOTA-cT84.66 demonstrated increased liver 
and spleen activity over time, and intestinal activity became vis-
ible at 48 h as biliary excretion of 64Cu occurred. In the case of 
either mAb, it must be considered that copper could have been 
excreted into the intestinal tract unbound to antibody through 
the normal copper processing function of the liver. This series 
of non-invasive imaging studies gave striking confirmation of 
the biodistributions previously determined by more traditional 
means, with the added accuracy of repeated measures in the 
same living mice, and the potential to use fewer animals to 
obtain equivalent results.
The most valuable information gained from these images, 
however, was to estimate tumor dosimetry based on region of 
interest (ROI) evaluation. Because 64Cu was only available on 
a bi-monthly basis at the time, tumors were implanted 14 days 
prior to the experiment. During this time, tumors were expected 
to grow to approximately 200 mg in size. Prior to the imag-
ing studies tumor growth was greater than expected, reaching 
800–900 mg, four times the size of the tumors in the traditional 
biodistribution studies. On the two-dimensional PET images 
(Fig. 2), the tumors displayed heterogeneity of dose distribution 
within the parenchyma in most cases, suggesting that the large 
tumors had developed hypovascularized and likely necrotic areas 
within the tumors. Including the entire tumor area within the 
ROI, the larger tumors accumulated twice the radioactivity that 
was measured in the initial biodistribution studies. However, 
with four times the volume, the resulting dose to the tumors was 
approximately half that calculated previously. The therapy mice 
were injected with radiation calculated to deliver the same dose 
(10 Gy) to a 200 mg tumor, regardless of the mAb administered. 
Correcting for injected activity, for 0.89 mCi of 64Cu-DOTA-
cBR96, the actual dose to the tumor was 4.31 Gy, and for 0.71 
mCi of 64Cu-DOTA-cT84.66, the dose was 4.56 Gy in the larger 
tumors in the PET dosimetry experiment. Within 5% of each 
other, these doses are remarkably similar, given the potential for 
individual mouse variability, the limitations of sacrificial stud-
ies, and the great disparity in tumor size between the traditional 
biodistribution studies and PET imaging. Although not repre-
sentative of the absolute dose administered in the therapy study, 
this result confirms that the dosimetry would have been similar 
between experimental groups in the therapy study.
PET dosimetry offers great advantages for future 64Cu ther-
apy studies. Preliminary dose-finding biodistribution studies can 
be accomplished using far fewer mice, and allowing statistical 
Figure 4. Kaplan-Meier plot of time to progression of tumor mass to 1 g. 
There was no statistically significant difference between control groups 
or between groups receiving 64Cu. There was a significant difference 
between control groups and those receiving 64Cu (p < 0.0001).
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0.71 mCi of 64Cu-DOTA-cT84.66 intravenously via the tail vein 
on day 1 of the study. Mice were anesthetized with isoflurane in a 
Plexiglas imaging chamber and lightly immobilized with gauze. 
PET imaging was performed using a Philips MOSAIC high 
resolution rodent PET scanner and CT imaging was performed 
using an ImTek microCAT II scanner. Each mouse was imaged 
for 15–60 min by PET and for 8 min by CT at 3, 24 and 48 h 
post-injection.
PET tumor dosimetry. High resolution imaging data was 
processed using the Philips Syntegra image fusion software for 
co-registration of anatomic (CT) and molecular (PET) imaging. 
Following previously published protocols,20,21 a region of inter-
est (ROI) was drawn around the complete area of the tumor, 
and the total number of counts/pixel/min was calculated. The 
total counts within the tumor area were compared to the total 
counts within a known standard dose of 64Cu for each mAb to 
calculate the percent injected dose to each tumor (% ID/organ) 
at each time point, from which the doses of radiation delivered 
to the tumors over the imaging period were estimated in rad/
mCi and mGy/MBq. Total absorbed dose was assumed to be 
averaged within the tumor without attempt to separate high and 
low-uptake regions of the tumors. The imaging results were also 
evaluated subjectively for distribution of radioactivity within soft 
tissues of the mouse body.
Therapy study. Fourteen days prior to the start of the study, 
outbred female nu/nu mice were inoculated with LS174T cells 
as described above. Mice were divided into three control groups 
(n = 10) and two experimental groups (n = 9). Control groups 
received either 0.15 of mL saline, 0.089 mg of unlabeled DOTA-
cBR96 or 0.071 mg of unlabeled DOTA-cT84.66, respec-
tively, administered intravenously via the tail vein on day 1 of 
the study. A control group of 64Cu-DOTA was not included, 
as an anticipated low calculated radiation dose would not be 
expected to be therapeutic if not targeted to the tumor and 
excretion would likely be extremely rapid. Experimental groups 
received either 0.89 mCi of 64Cu-DOTA-cBR96 or 0.71 mCi of 
64Cu-DOTA-cT84.66 intravenously via the tail vein on day 1 of 
the study. Mice were weighed daily and examined for signs of 
overt systemic toxicity (e.g., weight loss >20%, lethargy, diar-
rhea, cyanosis). Tumors were measured in three dimensions and 
tumor volume calculated by the formula length x width x depth 
x π/6 daily until tumor growth stabilized, then three times 
weekly. Mice were observed for adverse reactions on a twice 
daily basis. Mice were sacrificed if their tumor reached 3 g, body 
weight decreased >20%, the tumor ulcerated or the tumor inter-
fered with normal ambulation.
Statistical analysis. Comparison of groups in the therapy 
study was accomplished using a Kaplan-Meier log-rank analysis. 
Comparison of % ID/organ values was accomplished using one-
way analysis of variance (ANOVA). Differences were deemed sig-
nificant at the 95% confidence level (p ≤ 0.05).
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containing 2 x 106 LS174T colon tumor cells in the right pre-
femoral region via a 23 gauge needle. Tumors for the imaging 
study reached a mean weight of 863 mg in 14 days. Tumors for 
the therapy study reached a mean weight of 171 mg in 14 days.
Monoclonal antibodies. The methods used to prepare the 
conjugates and perform quality control evaluation have been 
previously described in reference 5. Briefly, the antibodies used 
in these experiments were conjugated at a 10:1 molar ratio of 
DOTA-OSSu:mAb for the human/murine chimeric antibody 
cBR96 and a 20:1 molar ratio of DOTA-OSSu:mAb for the 
human/murine chimeric antibody cT84.66. The conjugates 
were purified by extensive dialysis against 0.1 M ammonium 
citrate buffer, pH 5.5. These conjugation ratios yielded 1.26 
functional chelates per cBR96 mAb and 3.6 functional ch -
lates per cT84.66 mAb.5 Immunoreactivity and serum stabil-
ity were quantitative by ELISA methods for DOTA-cBR96,5 
and by reaction with purified antigen and SE-HPLC for 
DOTA-cT84.66.8
Antibody labeling. Copper-64 was produced on a biomedical 
cyclotron at Washington University School of Medicine by previ-
ously published methods.18 Conjugates were labeled with 64Cu 
to a specific activity of 10 μCi/μg in 0.1 M ammonium citrate, 
pH 5.5, for 1 h at 43°C.19 Diethylenetriaminepentaacetic acid 
(DTPA) was then added to a final concentration of 1 mM, and the 
reaction mixtures were let stand for 15 min at room temperature. 
The labeled mAbs were purified and exchanged into phosphate- 
buffered saline by gel-filtration spin column chromatography, 
using Bio-Spin 6 columns (Bio-Rad, Hercules, CA).19 Specific 
activity of labeling was determined prior to purification and radio-
chemical purity was determined after purification, by SE-HPLC 
using a Waters (Milford, MA) Delta 600 chromatograph 
equipped with a manual Rheodyne injector, a Waters 2487 dual 
wavelength UV detector, a Packard (Downers Grove, IL) 500TR 
Flow Scintillation Analyzer with a GAMMA-C flow cell for 64Cu, 
a Waters busSAT/IN analog-digital interface, and the Waters 
Millennium 32 software package. A Phenomenex (Torrance, CA) 
BioSep-SEC-S 3000 column (7.8 x 300 mm, 5 μm, 290 Å), an 







6.8 and a flow rate of 1.0 mL/min were used.
PET imaging. Fourteen days prior to the start of the study, 
six outbred female nu/nu mice were inoculated with LS174T 
cells as described above. Mice were divided into two groups 
(n = 3). Based on previously reported data in reference 5, respec-
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